
1. Technology overview
Ebenbuild GmbH is a company based at Holzstr. 28 in Munich, Germany. It builds virtual replicas of individual lungs by combining physics-based modeling, computational physiology and AI, drawing on research at the Technical University of Munich, for clinicians and pharmaceutical developers.
Aerogram is a cloud-based clinical decision support tool for mechanical ventilation. A clinician orders an Aerogram, AI extracts the 3D lung structure and pathology from a routine CT scan to build a patient-specific digital twin, and the system tests combinations of ventilator settings virtually to produce personalized ventilation maps. Ebenbuild also offers Twinhale, an in silico trial service that predicts inhaled drug deposition for pharmaceutical customers.
2. Highlighted features & specifications
- Lung digital twin: AI builds a patient-specific 3D replica from a routine CT scan.
- Ventilation simulation: combinations of ventilator settings are tested virtually on the twin.
- Ventilation maps: personalized maps help identify protective settings.
- Cloud delivery: the service is ordered and delivered through the cloud.
- Validation: predictions compared with EIT and 3D SPECT imaging in published studies.
- Twinhale: in silico trials predicting inhaled drug deposition, with results in about 2 weeks.
3. Potential application
ICUs in Vietnamese tertiary hospitals could use Aerogram to support ventilator settings for severe respiratory failure. Pharmaceutical and device companies could use Twinhale to design inhaled products. Medical universities could collaborate on lung modeling research.
4. Benefits
Reduces trial and error when choosing ventilator settings for each patient. Aims to reduce preventable lung damage and shorten ICU stays. Makes outcomes depend less on individual expertise. Uses a routine CT scan, with cloud-based delivery that needs no extra hardware.
5. Market trends & opportunities
Intensive care units seek personalized ventilation strategies as lung injury remains a major cause of death in ventilated patients, and drug developers use in silico methods to cut trial risk. Vietnam's tertiary hospitals with large ICUs could be early users, subject to regulatory clearance outside the EU.
6. Other information
Ebenbuild GmbH, Holzstr. 28, 80469 Munich, Germany. EIC Accelerator funding of EUR 2.3 million announced in July 2025. Validation studies published in 2025 and 2026. Twinhale collaborators listed include PARI, Pieris Pharmaceuticals and Aerogen. Regulatory status of Aerogram is not stated on the site.
One platform connecting startups, corporations, research institutions, regions and investors











Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
RETAIL E-COMMERCE: AI AND REAL-TIME DATA ARE TRANSFORMING HOW RETAIL BUSINESSES OPERATE








































